Enlivex to present Allocetra's therapeutic potential in inflammatory diseases at Israeli BioMed 2025 Conference.
PorAinvest
martes, 20 de mayo de 2025, 8:20 am ET1 min de lectura
ENLV--
Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This therapy aims to address chronic and life-threatening inflammatory diseases by resetting non-homeostatic macrophages [1].
The company's presentation will highlight Allocetra™'s therapeutic potential in inflammatory diseases. Preliminary data from a six-month interim readout in moderate knee osteoarthritis showed statistically significant reductions in pain (47%), improvement in joint function (46%), and decrease in stiffness (40%) [1]. Enlivex is currently advancing a broad clinical pipeline with Allocetra™, including multiple Phase I/II trials in osteoarthritis and psoriatic arthritis, with additional readouts expected in 2025 [1].
Enlivex's approach to macrophage reprogramming offers a promising strategy for immune system rebalancing and disease resolution. The company's presentation at the Israeli BioMed 2025 Conference will provide insights into the potential of Allocetra™ in treating inflammatory diseases, positioning Enlivex as a leader in the field of macrophage reprogramming immunotherapy [1].
References:
[1] https://www.marketscreener.com/quote/stock/ENLIVEX-THERAPEUTICS-LTD-56422776/news/Enlivex-Selected-to-Present-at-Israeli-BioMed-2025-Conference-50010352/
Enlivex Therapeutics has been selected to present at the Israeli BioMed 2025 Conference. The company's CEO will deliver a presentation titled "Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases". Enlivex's Allocetra cell therapy is designed to reset macrophages to their homeostatic state, addressing chronic and life-threatening inflammatory diseases.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has been selected to present at the upcoming Israeli BioMed 2025 Conference, scheduled from May 21 to 23 in Tel Aviv, Israel. The company's CEO will deliver a presentation titled "Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases" as part of the session "Personalized Pathways; Genetic and Cellular Based Therapies for Rare and Complex Diseases" [1].Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This therapy aims to address chronic and life-threatening inflammatory diseases by resetting non-homeostatic macrophages [1].
The company's presentation will highlight Allocetra™'s therapeutic potential in inflammatory diseases. Preliminary data from a six-month interim readout in moderate knee osteoarthritis showed statistically significant reductions in pain (47%), improvement in joint function (46%), and decrease in stiffness (40%) [1]. Enlivex is currently advancing a broad clinical pipeline with Allocetra™, including multiple Phase I/II trials in osteoarthritis and psoriatic arthritis, with additional readouts expected in 2025 [1].
Enlivex's approach to macrophage reprogramming offers a promising strategy for immune system rebalancing and disease resolution. The company's presentation at the Israeli BioMed 2025 Conference will provide insights into the potential of Allocetra™ in treating inflammatory diseases, positioning Enlivex as a leader in the field of macrophage reprogramming immunotherapy [1].
References:
[1] https://www.marketscreener.com/quote/stock/ENLIVEX-THERAPEUTICS-LTD-56422776/news/Enlivex-Selected-to-Present-at-Israeli-BioMed-2025-Conference-50010352/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios